Fig. 1
From: TP53 mutation prevalence in normal airway epithelium as a biomarker for lung cancer risk
a Subject group-specific mean mutation prevalence (mutations/bp) in the targeted TP53 exon regions (spanning 193 bp) among control non-cancer smokers (NCS) (N = 21), control non-cancer non-smokers (NCNS) (N = 8), all controls (NC ALL) (N = 29) and cancer (CA) (N = 30) subjects. Prevalence in AEC specimens from CA subjects was significantly higher compared with NC ALL (P < 0.001) while there was no significant difference between NCS and NCNS (Kruskal–Wallis). b Assessment of TP53 mutation signature patterns as prevalence (mutations/bp) according to nucleotide transition type. After Bonferroni adjustment, there was a significantly higher prevalence of C > A (P = 0.001), C > T (P = 0.0013), and T > C (P = 0.0024) in CA compared with NC ALL (Kruskal–Wallis test using a Chi-square distribution)